My response to TIAB regarding P.
Re: To infinity and beyond! Post# 195533
P Phase 2a has served its purpose as a POC trial IMO. The trial confirmed that P reduced CD4+ T cells in humans. These T cells were found to induce psoriasis.
"Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis."
https://www.ncbi.nlm.nih.gov/pubmed/10393847
F1ash pointed out that moderate to severe psoriasis patients have more CD4+ T cells and CD8+ T cells than mild psoriasis patients and people without psoriasis.
"A striking observation is the increased percentage of both CD4+ cells and CD8+ cells in patients with moderate-to-severe psoriasis as compared to mild psoriasis and normal subjects, without a change in CD4/CD8 ratio. So far, reports on the CD4+/CD8+ ratio in psoriasis have been at variance [10, 11]."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...po=1.31579
I think this bodes well for Phase 2b since the PP are moderate to severe psoriasis and the dosages are 300 mg & 400 mg vs. 200 mg in Phase 2a. A higher plasma concentration in P should lead to more CD4+ T reductions.
Re: To infinity and beyond! Post# 195533
P Phase 2a has served its purpose as a POC trial IMO. The trial confirmed that P reduced CD4+ T cells in humans. These T cells were found to induce psoriasis.
"Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis."
https://www.ncbi.nlm.nih.gov/pubmed/10393847
F1ash pointed out that moderate to severe psoriasis patients have more CD4+ T cells and CD8+ T cells than mild psoriasis patients and people without psoriasis.
"A striking observation is the increased percentage of both CD4+ cells and CD8+ cells in patients with moderate-to-severe psoriasis as compared to mild psoriasis and normal subjects, without a change in CD4/CD8 ratio. So far, reports on the CD4+/CD8+ ratio in psoriasis have been at variance [10, 11]."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...po=1.31579
I think this bodes well for Phase 2b since the PP are moderate to severe psoriasis and the dosages are 300 mg & 400 mg vs. 200 mg in Phase 2a. A higher plasma concentration in P should lead to more CD4+ T reductions.
7
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
